Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.71 |
| ▸ | SRC | P12931 | 16/20 | 0.64 |
| ▸ | EGFR | P00533 | 8/20 | 0.61 |
| ▸ | KDR | P35968 | 7/20 | 0.61 |
| ▸ | ABL1 | P00519 | 6/20 | 0.61 |
| ▸ | ABL2 | P42684 | 6/20 | 0.61 |
| ▸ | CDK1 | P06493 | 4/20 | 0.58 |
| ▸ | LCK | P06239 | 5/20 | 0.55 |
| ▸ | TEK | Q02763 | 4/20 | 0.55 |
| ▸ | CSK | P41240 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RGS12 | O14924 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15934520 | 0.86 | SRC (0.80) | BTKSRCEGFRKDRABL1 | |
| SCHEMBL1897340 | 0.86 | SRC (0.69) | BTKSRCEGFRKDRABL1 | |
| Cyanate SCHEMBL27871831 | 0.84 | BTK (0.75) | BTKSRCEGFRKDRABL1 | |
| SCHEMBL1898318 | 0.84 | BTK (1.00) | BTKSRCEGFRKDRABL1 | |
| SCHEMBL1898321 | 0.84 | BTK (1.00) | BTKSRCEGFRKDRABL1 | |
| SCHEMBL1901072 | 0.83 | SRC (0.82) | BTKSRCEGFRKDRABL1 | |
| SCHEMBL14646982 | 0.82 | SRC (0.64) | BTKSRCEGFRKDRABL1 | |
| SCHEMBL1906312 | 0.81 | BTK (1.00) | BTKSRCEGFRKDRABL1 | |
| SCHEMBL1906314 | 0.81 | BTK (1.00) | BTKSRCEGFRKDRABL1 | |
| SCHEMBL1906416 | 0.79 | BTK (1.00) | BTKSRCEGFRKDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505766-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505766-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| EP-2558099-A2 | KINASE INHIBITORS | The Regents Of The University Of California, San Francisco (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130035325-A1 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035325-A1 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035325-A1 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| CN-102711765-A | Kinase inhibitors | UNIV CALIFORNIA | 2012-10-03 | — | — | CN | disclosed |
| WO-2011060440-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060440-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035325-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | BTK 270/4885SRC 84/4885EGFR 347/4885 |
| US-20150045343-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | BTK 270/4885SRC 84/4885EGFR 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.